Co-crystals are crystalline materials composed of two or more different molecules, typically active pharmaceutical ingredients and co-crystal formers in the same crystal lattice. Tailoring of co-crystals can provide opportunities to not only enhance bioavailability and stability but also the processability of APIs during drug manufacturing.

In 2018, the US Food and Drug Administration published guidance clarifying the regulatory classification of pharmaceutical co-crystal solid-state forms for companies planning to submit new drug applications. This move has generated a lot of interest in the co-crystal field.

In this podcast, we talk to Andy Singh, Founder and CEO at Asha Pharma about how the use of co-crystals has evolved and what are the best approaches to screening and selecting co-crystals to identify the most viable ones to help find suitable development candidates.